Aquestive's Cash Runway Depends on Anaphylm Approval That May Not Come This Quarter

Aquestive Therapeutics (AQST) reports first-quarter 2026 results after the close on May 13, with a conference call scheduled for May 14 at 8:00 a.m. ET. The specialty pharmaceutical company faces a critical test as investors assess whether its PharmFilm® technology platform can deliver improving fundamentals and progress toward profitability. With analysts projecting a narrower loss than the prior year and the stock trading well below its consensus price target, this report will determine whether the company's pipeline advances and commercialization efforts can justify the bullish Wall Street outlook.

Part 1: Earnings Preview

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative medicines using its proprietary PharmFilm® technology, which delivers drugs via dissolvable oral films. The company operates both as a developer of its own products—including lead candidates Anaphylm™ for severe allergic reactions and AQST-108 for dermatological conditions—and as a Contract Development and Manufacturing Organization (CDMO) for licensees.

Earnings Expectations: Aquestive is expected to report a loss of $0.14 per share for Q1 2026 on revenue of approximately $10.90 million. The most recent quarter (Q4 2025) delivered a loss of $0.26 per share, representing a significant miss against the $0.13 estimate. Year-over-year, the consensus estimate reflects 41.67% improvement from the $0.24 loss reported in Q1 2025, signaling expectations for meaningful progress in narrowing losses.

Key Themes Heading Into Earnings:

Pipeline Progress and Regulatory Milestones: Investors will scrutinize updates on Anaphylm™ (dibutepinephrine) sublingual film for anaphylaxis treatment and AQST-108 topical gel for alopecia areata. Any advancement toward FDA approval or new clinical data from the AdrenaVerse™ platform could validate the company's technology and expand addressable markets. Management commentary on regulatory timelines and commercialization partnerships will be critical.

CDMO Revenue Stability and Growth: As the exclusive manufacturer of four commercialized products using PharmFilm® technology, Aquestive's licensing and royalty revenues provide crucial cash flow. Investors will watch for trends in CDMO demand, new partnership announcements, and whether this business segment can offset R&D spending while proprietary products advance through development.

Cash Runway and Path to Profitability: With the company still pre-profitability and burning cash, quarterly liquidity updates are essential. Analysts will focus on R&D expenditure trends, operating expense discipline, and management's guidance on how long current cash reserves can sustain operations. Any commentary on financing needs or strategic alternatives could move the stock significantly.

Analysts remain constructive despite recent execution challenges. The 8 Strong Buy ratings and $8.89 average price target (113% upside from current levels) reflect confidence in the PharmFilm platform's commercial potential, though the Q4 earnings miss and deteriorating technical signals suggest investors are waiting for concrete evidence of operational improvement.

Part 2: Historical Earnings Performance

Aquestive's recent earnings track record shows inconsistent execution with a troubling pattern of significant misses. Over the past four quarters, the company has missed estimates twice and beaten twice, but the misses have been far more severe than the beats.

The most recent quarter (Q4 2025) delivered the worst performance, with a $0.26 loss that missed the $0.13 estimate by 100%—double the expected loss. This followed two quarters of relatively modest variance: Q3 2025 saw a 22.22% beat (reporting $0.14 vs. $0.18 estimated), while Q2 2025 posted a minor 7.69% miss. The pattern began a year ago in Q1 2025 with a 41.18% miss, reporting a $0.24 loss against a $0.17 estimate.

The volatility in results—swinging from meaningful beats to substantial misses—suggests operational unpredictability that may concern investors. The Q4 deterioration is particularly notable, as it represents a sequential worsening from Q3's better-than-expected performance. This inconsistency makes the upcoming Q1 report critical: investors will be watching whether management can return to the improvement trajectory seen mid-2025 or if the Q4 setback signals deeper challenges in the business model.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Aquestive typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around Aquestive earnings shows moderate volatility with asymmetric risk. On the day of earnings (Day 0), the stock has moved an average of 3.28% with an intraday range of 5.32%, reflecting relatively contained pre-announcement positioning. However, the following session (Day +1) tells a different story: the average absolute move jumps to 6.40% with a much wider 11.53% intraday range, indicating that the market's true reaction unfolds after digesting the full report and management commentary.

The most dramatic post-earnings move came after the May 2025 report, when the stock plunged 19.65% on Day +1 despite a modest 2.15% gain on Day 0—a stark reminder of how conference call commentary can override initial reactions. More recently, the March 2026 report produced a 6.07% Day 0 gain followed by a 2.52% Day +1 decline, showing profit-taking after the initial enthusiasm. The November 2024 report demonstrated the downside risk, with the stock falling 6.70% on Day 0 and extending losses another 7.67% on Day +1.

Investors should prepare for potential double-digit intraday swings on the day following this report, with historical patterns suggesting the Day +1 session will be more volatile and directionally decisive than the initial after-hours reaction.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.60% expected move for the upcoming earnings report, which is significantly higher than the historical Day 0 average move of 3.28% but more aligned with the Day +1 average absolute move of 6.40%. This suggests options traders are anticipating above-average volatility, though not quite at the extreme levels seen in some past reports like the May 2025 event. The elevated implied move reflects uncertainty around whether management can deliver on the improved loss estimates after the disappointing Q4 miss.

Part 3: What Analysts Are Saying

Wall Street maintains a strongly bullish stance on Aquestive despite recent operational challenges. The consensus rating stands at 4.78 out of 5.0, with 8 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 9 analysts covering the stock. The average price target of $8.89 implies 113% upside from the current $4.16 price, with a range spanning from $6.00 (44% upside) to $11.00 (164% upside).

Analyst sentiment has remained unchanged over the past month, indicating that the Street's conviction in the PharmFilm platform and pipeline potential has held steady despite the Q4 earnings disappointment. The concentration of Strong Buy ratings—representing 89% of all recommendations—reflects confidence that Aquestive's proprietary technology and advancing clinical programs will eventually translate into significant shareholder value.

The wide gap between the current stock price and analyst targets suggests the market is demanding proof of execution before pricing in the optimistic scenario. Analysts appear to be looking through near-term losses to focus on longer-term commercialization opportunities, particularly around Anaphylm™ and the CDMO business expansion. However, the lack of any bearish ratings also indicates potential for downside if the company fails to demonstrate progress on key pipeline milestones or cash management in the upcoming report.

Part 4: Technical Picture

Aquestive enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing a 56% Sell signal—a notable weakening from 48% Sell one week ago and 40% Sell one month ago. This progressive deterioration reflects mounting technical pressure as the stock has failed to gain traction despite the bullish analyst outlook.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative heading into the report
• Medium-term (50% Sell): Matching sell signal in the intermediate timeframe suggests the weakness is not just a short-term phenomenon
• Long-term (100% Sell): Strong sell signal reflects significant weakness in the longer-term trend, with the stock well below its 200-day moving average

Trend Characteristics: The combination of Weak strength and Average direction suggests a stock in a shallow downtrend without strong conviction in either direction—a technically vulnerable setup heading into a potentially volatile earnings event.

The stock is trading at $4.16, positioned below its 5-day ($4.26), 10-day ($4.20), 20-day ($4.20), 100-day ($4.29), and 200-day ($4.86) moving averages. The only positive is that price remains above the 50-day moving average at $4.15, providing minimal near-term support.

The technical setup heading into earnings is cautionary, with the stock trapped below most key moving averages and showing deteriorating momentum across all timeframes. The 200-day moving average at $4.86 represents significant overhead resistance—17% above current levels—while the 50-day at $4.15 provides the only nearby support level. The weak technical picture suggests the stock will need a strong earnings beat and positive guidance to overcome the negative momentum, while any disappointment could accelerate the existing downtrend. Given the options market's 9.60% expected move and the stock's vulnerable positioning, traders should be prepared for heightened volatility in both directions.